Search

Your search keyword '"Costa, Vivian V."' showing total 7 results
Start Over Author "Costa, Vivian V." Publisher wiley
7 results on '"Costa, Vivian V."'

1. Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19

Author

de Oliveira Formiga, Rodrigo, primary, Amaral, Flávia C., additional, Souza, Camila F., additional, Mendes, Daniel A. G. B., additional, Wanderley, Carlos W. S., additional, Lorenzini, Cristina B., additional, Santos, Adara A., additional, Antônia, Juliana, additional, Faria, Lucas F., additional, Natale, Caio C., additional, Paula, Nicholas M., additional, Silva, Priscila C. S., additional, Fonseca, Fernanda R., additional, Aires, Luan, additional, Heck, Nicoli, additional, Starick, Márick R., additional, Queiroz‐Junior, Celso M., additional, Santos, Felipe R. S., additional, de Souza, Filipe R. O., additional, Costa, Vivian V., additional, Barroso, Shana P. C., additional, Morrot, Alexandre, additional, Van Weyenbergh, Johan, additional, Sordi, Regina, additional, Alisson‐Silva, Frederico, additional, Cunha, Fernando Q., additional, Rocha, Edroaldo L., additional, Chollet‐Martin, Sylvie, additional, Hurtado‐Nedelec, Maria Margarita, additional, Martin, Clémence, additional, Burgel, Pierre‐Régis, additional, Mansur, Daniel S., additional, Maurici, Rosemeri, additional, Macauley, Matthew S., additional, Báfica, André, additional, Witko‐Sarsat, Véronique, additional, and Spiller, Fernando, additional

Published
2023
Full Text
View/download PDF

2. Annexin A1 promotes timely resolution of inflammation in murine gout

Author

Galvão, Izabela, primary, Vago, Juliana P., additional, Barroso, Livia C., additional, Tavares, Luciana P., additional, Queiroz-Junior, Celso M., additional, Costa, Vivian V., additional, Carneiro, Fernanda S., additional, Ferreira, Tatiana P., additional, Silva, Patricia M. R., additional, Amaral, Flávio A., additional, Sousa, Lirlândia P., additional, and Teixeira, Mauro M., additional

Published
2017
Full Text
View/download PDF

3. Transmembrane TNF-α is sufficient for articular inflammation and hypernociception in a mouse model of gout

Author

Amaral, Flávio A., primary, Bastos, Leandro F. S., additional, Oliveira, Thiago H. C., additional, Dias, Ana C. F., additional, Oliveira, Vívian L. S., additional, Tavares, Lívia D., additional, Costa, Vivian V., additional, Galvão, Izabela, additional, Soriani, Frederico M., additional, Szymkowski, David E., additional, Ryffel, Bernhard, additional, Souza, Danielle G., additional, and Teixeira, Mauro M., additional

Published
2015
Full Text
View/download PDF

4. NLRP3 inflammasome–mediated neutrophil recruitment and hypernociception depend on leukotriene B4 in a murine model of gout

Author

Amaral, Flávio A., primary, Costa, Vivian V., additional, Tavares, Livia D., additional, Sachs, Daniela, additional, Coelho, Fernanda M., additional, Fagundes, Caio T., additional, Soriani, Frederico M., additional, Silveira, Tatiana N., additional, Cunha, Larissa D., additional, Zamboni, Dario S., additional, Quesniaux, Valerie, additional, Peres, Raphael S., additional, Cunha, Thiago M., additional, Cunha, Fernando Q., additional, Ryffel, Bernhard, additional, Souza, Daniele G., additional, and Teixeira, Mauro M., additional

Published
2012
Full Text
View/download PDF

7. Effects of a pro-resolving drug in COVID-19: preclinical studies to a randomized, placebo-controlled, phase Ib/IIa trial in hospitalized patients.

Author

Almeida PRJ, Periard AM, Tana FL, Avila RE, Milhorato LB, Alcantara KMM, Resende CB, Serufo AV, Santos FR, Teixeira DC, Queiroz-Junior CM, Fonseca TCM, Silva BLV, Costa VV, Souza RP, Perretti M, Jonassen TEN, and Teixeira MM

Subjects
Humans, Animals, Male, Middle Aged, Female, Mice, Double-Blind Method, Aged, Adult, Cytokines metabolism, Hospitalization, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear metabolism, Mice, Inbred C57BL, COVID-19 Drug Treatment, COVID-19, SARS-CoV-2 drug effects
Abstract

Introduction: Pro-resolving molecules may curb disease caused by viruses without altering the capacity of the host to deal with infection. AP1189 is a melanocortin receptor-biased agonist endowed with pro-resolving and anti-inflammatory activity. We evaluated the preclinical and early clinical effects of treatment with AP1189 in the context of COVID-19., Methods: C57BL/6j mice were infected intranasally with MHV-A59 or hK18-ACE2 mice with SARS-CoV-2. AP1189 (10 mg·kg -1 , BID, s.c.) was given to the animals from day 2 and parameters evaluated at day 5. Human PBMCs from health donors were infected with SARS-CoV-2 in presence or absence of AP1189 and production of cytokines quantified. In the clinical study, 6 patients were initially given AP1189 (100 mg daily for 14 days) and this was followed by a randomized (2:1), placebo-controlled, double-blind trial that enrolled 54 hospitalized COVID-19 patients needing oxygen support. The primary outcome was the time in days until respiratory recovery, defined as a SpO 2  ≥ 93% in ambient air., Results: Treatment with AP1189 attenuated pulmonary inflammation in mice infected with MHV-A59 or SARS-CoV-2 and decreased the release of CXCL10, TNF-α and IL-1β by human PBMCs. Hospitalized COVID-19 patients already taking glucocorticoids took a median time of 6 days until respiratory recovery when given placebo versus 4 days when taking AP1189 (P = 0.017)., Conclusion: Treatment with AP1189 was associated with less disease caused by beta-coronavirus infection both in mice and in humans. This is the first demonstration of the effects of a pro-resolving molecule in the context of severe infection in humans., (© 2024 British Pharmacological Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results